Exploratory Biomarker Analysis of Trastuzumab Deruxtecan in DESTINY-Gastric01, a Randomized, Phase 2, Multicenter, Open-Label Study in Patients with HER2-positive or -Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
ANNALS OF ONCOLOGY（2021）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined